Supplementary Figure S2 from Obinutuzumab Pretreatment As a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

Supplementary Figure S2. Percent reduction in B cell numbers and B cell/T cell ratios in human CD20 transgenic mice treated with obinutuzumab or rituximab in A, Spleen and B, Lymph nodes. C, Reduction in splenic marginal zone B cells in human CD20 transgenic mice treated with obinutuzumab or rituximab (n = 2 per group).